The sector ETFs present a different picture than the broader averages.
The news sent shares of the genome editing company skyward after the stock had been basing for months.
There's a split growing at the FOMC as to just how transitory the current burst of consumer level inflation actually is.
Let's review the charts and indicators.
Clearside Biomedical and Omeros Corp. both have promising products that should win regulatory approval in the coming months.
CNC has been a hard stock to trade and to analyze
My recommendation is not for the shy, timid, or new trader.
Investors can now look to buy shares of this biotech firm.
Traders should approach PKI from the long side at current levels.
This drugmaker is making a historic upside breakout. Let's check the charts.